BMI View: We expect the Lithuanian pharmaceutical market to continue to develop steadily over thecoming years, on account of demographic and epidemiological factors. However, its small populationand downward pressures on prices will continue to hamper the overall potential earnings in the countryfor pharmaceutical companies. Nevertheless, niche areas, such as biopharmaceuticals, will remain ofinterest to foreign majors, also from the point of view of exports.Headline Expenditure Projections?? Pharmaceuticals: LTL1.74bn (US$647mn) in 2012 to LTL1.85bn (US$720mn) in 2013; +6.7%in local currency terms and +11.3% in US dollar terms. Local currency forecast slightly u...
No comments:
Post a Comment